Your SlideShare is downloading. ×
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Transforming Pharmaceutical Operational Performance with Supply Chain Traceability
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Transforming Pharmaceutical Operational Performance with Supply Chain Traceability

2,203

Published on

Supply chain traceability and trading partner collaboration can bring significant benefits to all participants in the global pharmaceutical supply chain. SupplyScape's consulting leaders review the …

Supply chain traceability and trading partner collaboration can bring significant benefits to all participants in the global pharmaceutical supply chain. SupplyScape's consulting leaders review the key considerations and potential benefits of traceability technologies when combined with track and trace strategies.

Published in: Health & Medicine, Business
1 Comment
2 Likes
Statistics
Notes
No Downloads
Views
Total Views
2,203
On Slideshare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
378
Comments
1
Likes
2
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • The focus has always on the solution - & folding the appropriate technology into the desired end state…. Solving for different kinds of product problems – counterfeit, up-label, adulteration Diversion SC Efficiency
  • A delay in launch can cost a company an average of $15 milllion dollars per drug, per day for a potential blockbuster. (based on IMS sales) Earnings of 10 to 30% at risk Increasing pressure for line extensions Driving up number of unique products the channel must handle The average cost of new drug development for a successful New Molecular Entity ranges from $800M to $900B according to several industry studies and Purdue University. A drug with peak annual sales of $1 Billion generates extra $600million (NPV) over its lifetime if peak sales attained 2 years earlier.
  • BRIC countries offer greater growth, infrastructure challenges, product security challenges
  • A&D – constant changing grid strategically – serial mgt headache operationally Outsourcing 3PL, CPOs Capability – if the mandates are to be taken seriously, our client base will have to move at a rate of 14 lines per month to make the 2015 deadline Reliability and Flexibility to meet cycle stock and safety stock requirements (lead time variation)
  • Transcript

    • 1. Transforming Pharmaceutical Business Performance: The Supply Chain as a Strategic Enabler Robin Koh and Yun Kang SupplyScape, Inc.
    • 2. Leveraging technology with supply chain domain expertise… … to deliver industry’s most relevant Track & Trace based Supply Chain Solutions SupplyScape Driving Product Integrity and Additional Business Value Turning Data Into Actionable Knowledge Pedigree, Serialization & Authentication Business Collaboration & Traceability
    • 3. A Safe & Secure Chain The Evolution Continues Improving Accountability & Control Product Security Transaction Security Physical Auth. Features Serialization Trace Track Authentication Pedigree Pharmaceutical Co Wholesaler Pharmacy Chain of Custody Security Individual Product Security
    • 4. Agenda
      • Trends Driving a Focus on the Supply Chain
      • Track & Trace Implications on the Supply Chain
      • Case Study
      • Suggested Next Steps
    • 5. Patent Expiry and Generic Substitution An Increased Emphasis on Efficiency & Cost US Patent Sales at Risk Number of Generic Filings Impacts on price per dose
    • 6. Global Growth Strategies Emerging Markets Offer Growth, Challenges Source: IMS Market Data, 2007 Year over Year Growth
    • 7. Product Security Incidents The need for better control on Supply Chains
      • Incidents reported:
        • Counterfeits
        • Diversions
        • Thefts
      (Prescription only, not including Biologics) Worldwide Commercial Impact 65 09 56 08 49 07 44 06 39 05 75 10 04 35 ( Counterfeit drugs — $ billions ) Sources: Center for Medicines in the Public Interest Global Pharma Safety Incidents Sources: Organisation for Economic Co-operation and Development 964 04 196 02 484 03 1,123 05 1,412 06 1,759 07 US Drug Recalls Sources: FDA (CDER) Drug Counterfeit Incidents Investigated Sources: FDA 58 04 27 02 21 01 6 00 11 99 30 03 32 05 54 06 31 07 (# Investigation cases opened)
    • 8. Select Strategic Transformation Programs
    • 9. Supply Chain Traceability Increasing Global Requirements & Complexity (1) Hemophilia products only Est. 2013 Yes TBD Batch # Linear Barcode - TBD Batch Level Korea In effect Batch # Data Matrix / QR Code Biologics Only – Unit Japan In effect Yes SGTIN -96 Serial # - TBD Data matrix Sales Pack Ireland 1 TBD Yes TBD Product Code, Batch #, Date of Mfg, Expiration Date Data Carrier – TBD Sales Pack Brazil Oct 31, 2008 Yes 6 digits - Numeric 9 digits - Numeric Serial # 4 digit – Numeric check digit manufacturer code + serial number + check digits Code 128c Sales Pack China 16 digits - Numeric Including 8 digit sequence # Product License # + Random Sequence # Product code, Serial # Reimbursement data CIP code 13, Lot #, Expiry date Product Code, Batch #, Unit #, Expiry date National Reg. Number , Sequential # Sequential # Product License # Data Required AI(01) + AI(21) 14 digit – Product code 20 Digit – Serial number 13 digits - Numeric TBD 13 digits - Numeric 12 digits - Numeric 9 digits - Numeric 1 letter for Drug Class + 9 digit Numeric Data Format Turkey France Spain Greece Belgium Italy Country Start – 01/08 End – 12/10 Yes Data matrix Lot In effect Yes Code 39 Sales Pack Jan 1, 09 Yes GS1 standard (Data Matrix ECC 200 or GS1 128) Sales pack, transport unit In effect Yes EAN 13 Sales Pack Data matrix on vignette TBD Yes Data Carrier TBD – PDF 417 / Data matrix Sales Pack In effect Yes EAN 128 Sales Pack I2/5 Timeline Mandatory Data Carrier Tracking Level
    • 10. Agenda
      • Trends Driving a Focus on the Supply Chain
      • Track & Trace Implications on the Supply Chain
      • Case Study
      • Suggested Next Steps
    • 11. Supply Network Design Impact of Track & Trace Technologies PharmaCo Distributor Pharmacy Customs CMO/CPO Globalization Acquisitions & Divestitures Outsourcing Capability Constraints Reliability Flexibility
    • 12. Inventory Management The Systematic Reduction of Uncertainty
      • Supply Side
      • Supplier Integration/Collaboration
      • Inventory Visibility
      • Cycle stock/Safety Stock
      • Demand Side
      • Forecasting
      • Actual Demand
      • Rate of Depletion
      • Location
      • Shrinkage
      Cost Service Time Inventory Min Max
    • 13. Other Supply Chain Initiatives Supply Chain Rationalization KPIs Reverse Logistics Pricing Programs Description Opportunity for Track & Trace
      • Rationalizing the number of supply chain partners for better control on product distribution
      • Understanding the role of additional information in internal & external Process and Result measures
      • Improving visibility into the qty and terms of products being returned to organization
      • Wholesaler and pharmacy register the drug sold to Health Authority, and PharmaCo uses this info to pay discount to wholesaler
      • Track & Trace technologies as an enabler for greater accountability of products
      • Impact of granular information on Write-offs, Stock-outs, Service Levels, Fill Rates etc.
      • Track & Trace technologies can provide visibility into the age of trade inventory and exact terms of sale
      • Free Pricing is a complex system that can be simplified by bypassing much of the data recording and facilitating the verification process by the PharmaCos.
    • 14. Agenda
      • Trends Driving a Focus on the Supply Chain
      • Track & Trace Implications on the Supply Chain
      • Case Study
      • Suggested Next Steps
    • 15. Case Study #1 Overview
      • A Leading Global Pharmaceutical Manufacturer
      • Objective:
        • To understand and quantify benefits in product security and business practice improvements enabled by Track & Trace
      • Key Issues:
        • A few top-selling product lines highly counterfeited and diverted
        • Faced with various global serialization mandates, and in need of justification for what was expected to be substantial investment
        • Integrated production network that makes localized approach challenging
    • 16. Case Study #1 Operational Areas Investigated Product Security Trade Financials Supply Chain Efficiency Out-of-Stock Reduction (Direct Channel) Anti-Counterfeit & Diversion Returns Management Theft & Shrinkage Reduction Clinical Trials Supply Chain Product Complaints Management & Resolution Shelf-life Management Chargeback Management New Product Launch Management Demand Forecasting & Planning Rebates Management Government Pricing Consignment Inventory / VMI
    • 17. Case Study #1 Three Different Approaches Used To Estimate Counterfeit Revenue Loss Online Pharmacy Model
      • Treat on-line pharmacy to be major source of counterfeit, unauthorized generics, diverted.
      • Determine amount of counterfeit purchased on-line
      Overall Market Size Model
      • Estimate market size by various patient group
      • Determine different between estimated market and actual sales
      Global Seizures Model
      • Utilize actual seizure data
      • Derive amount of counterfeit sold from seized API
      Revenue Loss Estimate 1 2 3
    • 18. Case Study #1 Returns Problem Decomposed Returned Products Direct Returns Indirect Returns Sold on Contract Not Sold on Contract Sold on Contract Not Sold on Contract
    • 19. Case Study #1 Returns Reconciliation – Issues and Opportunities
      • Unable to tie individual returned items to the original purchase. Credit is issued based on most recent WAC
      • Difficult to differentiate whether the returns are ‘legitimate’ or not.
        • This is turn poses challenges in enforcing the terms and conditions of contract
      • Returns processing is labor intensive, requiring manually reading and typing the lot #
      Business Issues/Challenges Opportunities
      • Improved return goods accuracy by issuing credit based on actual purchase price
      • Serial number on the items is tied to the transaction identifier (invoice #, PO #) that can be used to identify to whom the product was sold to  identify ‘illegitimate’ returns
      • Scanning serial number rather than typing lot # results in more efficient returns processing
    • 20. Case Study #1 Hard Savings Identification Yearly Benefits (unit: $ Thousand) Supply Chain & Trade Financials – I Supply Chain & Trade Financials – II Total Product Security Realizable unilaterally by Client Requires data sharing with TP Benefit A Benefit B Benefit C Benefit D Benefit E
    • 21. Case Study #1 Key Success Factor: Getting Downstream Partners to Participate
    • 22. Case Study #1 Key Takeaways
      • As expected, most attractive benefits require collaboration from supply chain
        • Internally realizable benefits do exist, but not as sizable
      • May need to look at areas other than finished goods for internally realizable, compelling benefits
        • Clinical trials, samples, reusable assets, etc.
        • Utilize the same infrastructure for Track & Trace
      • Some benefits require policy changes to be accompanied
      • Data sharing can lead to significant benefit
        • Manufacturers can do so much with data, if they can get it
        • Why would the downstream partners share data?
    • 23. Case Study #2:
      • A leading chain drug store
      • Objective:
        • To understand the potential benefits of Track & Trace enablers
      • Key Issues:
        • Faced with various regulatory requires for Track & Trace
        • Pressure for margin improvement
        • Complexity in operation - # of SKUs, variety in the form and shape, # of locations, etc.
    • 24. Frequency of manual checking of aging Monthly Typical man-hours spent each time X hours Average hourly wage $ Y # of stores Z Today’s practice ~ $ XX M Business benefit
        • Monitors exp-date of individual bottles
        • Eliminate need to check for every bottles in store
      Man-hour reduction due to T&T ~ X % (incl manual searching & checking, creating and managing current tags, etc.) ePedigree process How T&T can help Stores Case Study #2 Shelf Life Management and Control Made Easier at Store-level
    • 25.
        • Inaccurate supplier mis-pick
        • T&T picking is a self-auditing process, with additional verification step before sending to stores
        • Expected to reduce picking of wrong items and quantity
        • Improvement above 80% expected
        • Minimal impact
        • Individual item tracking allows monitoring of inactive bottles/units in store and generate warnings
        • Otherwise, minimal impact
        • T&Tputs in place a disciplined procedure for returns and transfers to be updated into the system
      Root causes of inaccuracy % accountable for inaccuracy How ePedigree can help X % Y % Z % V % ~ XX % PI Improvement %
        • Dispensing error
        • Theft & misplacement
        • Unreported transfers & returns
      % improvement by T&T 50 % 0 % 0 % 50 % Stores Case Study #2 Perpetual Inventory Accuracy Improvement Identified
    • 26. Cycle count frequency Daily Typical man-hours spent each time ~X min Average hourly wage $ Y # of stores Z Today’s practice ~ $ XX M Business benefit PI accuracy improvement ~ XX % % reduction in cycle count efforts ~ X % (excluding controlled drugs) ePedigree process Stores Case Study #2 Inventory Accuracy Leads to Potential Reduction in Cycle Count Effort
    • 27. % of scripts with OOS X % # of scripts/week/store Y Avg retail value of script $ Z Avg markup % V % Out-of-stock (OOS) relevant status Leave for a competitor nearby ~ 5 % Leave for another ABS store ~ 15 % Accept partial fill and/or ~ 80 % return some other time Patient reaction to OOS Ordering
        • Exceptional demand
        • Inappropriate parameters in sys
        • Item not in masterfile
        • Supplier OOS
        • Supplier mis-pick
        • Operational interruptions/ delay
        • Receiving error
        • Dispensing error
        • Theft & misplacement
        • Unreported transfers & returns
      Supplier delivery failure Inaccurate perpetual inventory Root causes of OOS % accountable for OOS % improvement by Track & Trace ~ X % ~ Y % ~ Z % ~ 0 % ~ 0 % ~ 30 % ~ $ XX M Business benefit Stores Case Study #2 Inventory Accuracy Also Leads to Out-of-Stock Reduction at Stores
    • 28. Sample on-hand qty of an item at DC A
        • If products are received and made available for sale faster, the order point can be reduced
        • Lower order point results in lower average on-hand inventory
      Rationale for inventory reduction ~ $ XX M Business benefit
      • Assumptions:
      • Inventory holding cost is X% of inventory value per year.
      • Build-to-week is 0.8 for DC A
      • Avg receiving hour for a PO is 6 hours currently, and is reduced to 4 hours
      DC Case Study #2 Inventory Accuracy Leads to Similar Operational Savings at DC Level Productivity Increase in Receiving Leads to Potential Inventory Reduction Order point = 2880
    • 29. Key Takeaways
      • Case Study #2:
        • Overall benefit at the store level order of magnitude higher, due to scaling factors
        • Rather than a single large benefit area, business case will most likely exist in sum of smaller ones
      • Overall
        • Benefits do exist at all segments of supply chain.
        • It’s matter of identifying where it works at each party, which will most likely be very different for both parties.
          • Type of benefit
          • Prioritization on product lines, locations, timing, etc.
          • Beyond operational
        • There are evolutionary opportunities, and they are revolutionary ones.
    • 30. Agenda
      • Trends Driving a Focus on the Supply Chain
      • Track & Trace Implications on the Supply Chain
      • Case Study
      • Suggested Next Steps
    • 31. What Top Pharmaceutical Companies Need To Be Able To Address Today
      • Compliance responsibilities around the globe
        • Localized approach vs integrated
        • Balance between doing too much vs. taking too much risk
      • Alignment between compliance, product security, and business value initiatives
        • Prioritized implementation plan
      • Alignment between US efforts and global needs
        • Need for greater supply chain control and closer customer access
        • Manifested by strong trends such as wholesaler consolidation, direct distribution, quota system, free-pricing
      • Getting the downstream trading partners aligned
        • Negotiating from the position of strength
        • Knowing what and how much to give and get
    • 32. Business Opportunities in Supply Chain Traceability
      • What if you could?
      • Leverage investments in product serialization initiatives to drive a higher return on product and brand protection?
      • Increase new product launch success by ensuring proper supply into key markets?
      • Establish a global network of trading partners to provide greater visibility into distribution channels ?
      • Overcome barriers to entry into new markets by more efficiently addressing local distribution requirements?
      • Facilitate financial reconciliation across chargeback, rebate, and re-imbursements across your supply network?
    • 33. Next Steps Get Started on Improving Supply Chain Performance Contact Mary Hall today to schedule a consultation! 781.503.7462, mhall@supplyscape.com Visit SupplyScape.com to learn more www.supplyscape.com

    ×